TY - JOUR
T1 - Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction
AU - MUSCAT-HF Study Investigators
AU - Nakashima, Mitsutaka
AU - Miyoshi, Toru
AU - Ejiri, Kentaro
AU - Kihara, Hajime
AU - Hata, Yoshiki
AU - Nagano, Toshihiko
AU - Takaishi, Atsushi
AU - Toda, Hironobu
AU - Nanba, Seiji
AU - Nakamura, Yoichi
AU - Akagi, Satoshi
AU - Sakuragi, Satoru
AU - Minagawa, Taro
AU - Kawai, Yusuke
AU - Nishii, Nobuhiro
AU - Fuke, Soichiro
AU - Yoshikawa, Masaki
AU - Nakamura, Kazufumi
AU - Ito, Hiroshi
AU - Ejiri, Kentaro
AU - Miyoshi, Toru
AU - Nakamura, Kazufumi
AU - Ito, Hiroshi
AU - Kihara, Hajime
AU - Hata, Yoshiki
AU - Nagano, Toshihiko
AU - Takaishi, Atsushi
AU - Toda, Hironobu
AU - Namba, Seiji
AU - Nakamura, Yoichi
AU - Akagi, Satoshi
AU - Sakuragi, Satoru
AU - Minagawa, Taro
AU - Kawai, Yusuke
AU - Nishii, Nobuhiro
AU - Sato, Tetsuya
AU - Fuke, Soichiro
AU - Yoshikawa, Masaki
AU - Sugiyama, Hiroyasu
AU - Imai, Michio
AU - Gotoh, Naoki
AU - Segawa, Tomonori
AU - Noda, Toshiyuki
AU - Koshiji, Masatoshi
AU - Kajikawa, Yutaka
AU - Morita, Hiroshi
AU - Yoshida, Masashi
AU - Doi, Masayuki
AU - Oka, Takafumi
N1 - Funding Information:
This work was supported by Novartis Pharma K. K.
Publisher Copyright:
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
PY - 2021
Y1 - 2021
N2 - Aims: Sodium glucose co-transporter 2 inhibitors have diuretic effects in both patients with glycosuria and with natriuresis. We sought to assess the effect of luseogliflozin on estimated plasma volume (ePV) in patients with type 2 diabetes and heart failure with preserved ejection fraction (HFpEF). Methods and results: This study was a post-hoc analysis of the MUSCAT-HF trial (UMIN000018395), a multicentre, prospective, open-label, randomized controlled trial that assessed the effect of 12 weeks of luseogliflozin (2.5 mg, once daily, n = 83) as compared with voglibose (0.2 mg, three times daily, n = 82) on the reduction in brain natriuretic peptide (BNP) in patients with type 2 diabetes and HFpEF. The analysis compared the change in ePV calculated by the Straus formula from baseline to Weeks 4, 12, and 24, using a mixed-effects model for repeated measures. We also estimated the association between changes in ePV and changes in other clinical parameters, including BNP levels. Luseogliflozin significantly reduced ePV as compared to voglibose at Week 4 {adjusted mean group-difference −6.43% [95% confidence interval (CI): −9.11 to −3.74]}, at Week 12 [−8.73% (95%CI: −11.40 to −6.05)], and at Week 24 [−11.02% (95%CI: −13.71 to −8.33)]. The effect of luseogliflozin on these parameters was mostly consistent across various patient clinical characteristics. The change in ePV at Week 12 was significantly associated with log-transformed BNP (r = 0.197, P = 0.015) and left atrial volume index (r = 0.283, P = 0.019). Conclusions: Luseogliflozin significantly reduced ePV in patients with type 2 diabetes and HFpEF, as compared with voglibose. The reduction of intravascular volume by luseogliflozin may provide clinical benefits to patients with type 2 diabetes and HFpEF.
AB - Aims: Sodium glucose co-transporter 2 inhibitors have diuretic effects in both patients with glycosuria and with natriuresis. We sought to assess the effect of luseogliflozin on estimated plasma volume (ePV) in patients with type 2 diabetes and heart failure with preserved ejection fraction (HFpEF). Methods and results: This study was a post-hoc analysis of the MUSCAT-HF trial (UMIN000018395), a multicentre, prospective, open-label, randomized controlled trial that assessed the effect of 12 weeks of luseogliflozin (2.5 mg, once daily, n = 83) as compared with voglibose (0.2 mg, three times daily, n = 82) on the reduction in brain natriuretic peptide (BNP) in patients with type 2 diabetes and HFpEF. The analysis compared the change in ePV calculated by the Straus formula from baseline to Weeks 4, 12, and 24, using a mixed-effects model for repeated measures. We also estimated the association between changes in ePV and changes in other clinical parameters, including BNP levels. Luseogliflozin significantly reduced ePV as compared to voglibose at Week 4 {adjusted mean group-difference −6.43% [95% confidence interval (CI): −9.11 to −3.74]}, at Week 12 [−8.73% (95%CI: −11.40 to −6.05)], and at Week 24 [−11.02% (95%CI: −13.71 to −8.33)]. The effect of luseogliflozin on these parameters was mostly consistent across various patient clinical characteristics. The change in ePV at Week 12 was significantly associated with log-transformed BNP (r = 0.197, P = 0.015) and left atrial volume index (r = 0.283, P = 0.019). Conclusions: Luseogliflozin significantly reduced ePV in patients with type 2 diabetes and HFpEF, as compared with voglibose. The reduction of intravascular volume by luseogliflozin may provide clinical benefits to patients with type 2 diabetes and HFpEF.
KW - Estimated plasma volume
KW - Heart failure with preserved ejection fraction
KW - Luseogliflozin
KW - Sodium glucose co-transporter 2 inhibitors
KW - Voglibose
UR - http://www.scopus.com/inward/record.url?scp=85118628134&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118628134&partnerID=8YFLogxK
U2 - 10.1002/ehf2.13683
DO - 10.1002/ehf2.13683
M3 - Article
C2 - 35267246
AN - SCOPUS:85118628134
JO - ESC heart failure
JF - ESC heart failure
SN - 2055-5822
ER -